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Abstract
Background: Delirium is an acute state of brain dysfunction characterised by fluctuating inattention and cognitive
disturbances, usually due to illness. It occurs commonly in the intensive care unit (ICU), and it is associated with
greater morbidity and mortality. It is likely that disturbances of sleep and of the day-night cycle play a significant
role. Melatonin is a naturally occurring, safe and cheap hormone that can be administered to improve sleep. The
main aim of this trial will be to determine whether prophylactic melatonin administered to critically ill adults, when
compared with placebo, decreases the rate of delirium.
Methods: This trial will be a multi-centre, randomised, placebo-controlled study conducted in closed ICUs in
Australia. Our aim is to enrol 850 adult patients with an expected ICU length of stay (LOS) of 72 h or more. Eligible
patients for whom there is consent will be randomised to receive melatonin 4 mg enterally or placebo in a 1:1 ratio
according to a computer-generated randomisation list, stratified by site. The study drug will be indistinguishable
from placebo. Patients, doctors, nurses, investigators and statisticians will be blinded. Melatonin or placebo will be
administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first. Trained
staff will assess patients twice daily to determine the presence or absence of delirium using the Confusion
Assessment Method for the ICU score. Data will also be collected on demographics, the overall prevalence of
delirium, duration and severity of delirium, sleep quality, participation in physiotherapy sessions, ICU and hospital
LOS, morbidity and mortality, and healthcare costs. A subgroup of 100 patients will undergo polysomnographic
testing to further evaluate the quality of sleep.
Discussion: Delirium is a significant issue in ICU because of its frequency and associated poorer outcomes. This trial
will be the largest evaluation of melatonin as a prophylactic agent to prevent delirium in the critically ill population.
This study will also provide one of the largest series of polysomnographic testing done in ICU.
Trial registration: Australian New Zealand Clinical Trial Registry (ANZCTR) number: ACTRN12616000436471.
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Background
Delirium is a state of acute organic brain dysfunction
with fluctuating disturbances of attention and cognition
which occurs as a direct consequence of an underlying
medical condition [1]. It is particularly common in
patients in intensive care units (ICUs), with a wide range
of prevalence ranging between 11% and 83% reported in
the literature [2–5]. Researchers in a multi-centre study
that included one of the participating hospitals of this
trial reported a delirium prevalence of 45% [5], whereas
a preliminary audit for this trial at the two primary sites
demonstrated a delirium prevalence of 52% when evalu-
ating patients with an expected ICU length of stay (LOS)
of more than 24 h.
Delirium in intensive care is associated with worse out-
comes. These include higher mortality (estimated as a 10%
increase in the relative risk of death for each day of delir-
ium) [6–10], more time on a ventilator [9–11], unplanned
removal of tubes and catheters [10], increased use of phys-
ical restraints [11], increased requirement for tracheos-
tomy, greater post-operative complications [12], poorer
functional status, cognitive impairment [7, 9, 13, 14],
increased hospital and ICU LOSs [8, 11, 12], increased
medical costs [15], higher risk of dementia [7, 13] and
greater likelihood of admission to residential care [7].
The aetiology of delirium is multi-factorial [16]. In the
critical care setting, it is likely that disturbances of sleep
and of the normal circadian rhythm play a significant
role [17]. Sleep deprivation may occur as a result of
environmental disturbances, loss of normal day-night
routine, critical illness itself and patient treatments.
However, although sleep disturbances have been demon-
strated to predispose individuals to post-operative delir-
ium, sleep problems and their relationship to delirium in
ICU remain relatively unexplored [18, 19].
In the clinical setting delirium can be approached with
prevention strategies or treatment strategies, with the
former appearing to be more effective. Authors of a
recent meta-analysis [20] reported 8 of 15 preventative
studies were successful, compared with 1 of 10 treat-
ment studies, in terms of reducing delirium incidence
and duration. There are several non-pharmacological
strategies used for preventing delirium in ICU, but there
are no pharmacological strategies that are used routinely
[6, 20]. Reasons for this include a lack of clear evidence,
limited pathophysiological understanding, potential side
effects, cost and difficulties identifying which patients
will benefit [21, 22].
Good-quality sleep at night is rapidly being recognised
as an important aspect of delirium prevention [19].
Melatonin is a natural hormone secreted by the pineal
gland, which helps in the regulation of the sleep-wake
cycle [23]. It is stimulated by low light, peaking during
the main sleep period [24–26]. Melatonin can be given
exogenously. In healthy volunteers, it decreases sleep on-
set latency, increases sleep efficiency and increases total
sleep duration [27]. It also increases the duration of
rapid eye movement (REM) sleep, which is thought to
have a positive effect on health and healing [28]. It is in-
expensive, has an excellent safety profile and is widely
used in the community [29–31]. Critical illness causes
deregulation of melatonin secretion by the pineal gland,
and light and darkness fail to restore its normal pattern
of secretion [32, 33]. Serum melatonin levels are found
to be lower after surgery, in delirious post-surgical pa-
tients and in those receiving opioids [25, 34]. Studies
have also demonstrated that exogenous melatonin is well
absorbed enterally in critically ill patients [35].
Melatonin has previously been evaluated for the treat-
ment of delirium, but only five trials have put it to the
test as a prophylactic agent. Sultan and colleagues [36]
evaluated prophylactic melatonin in patients requiring
elective hip replacement surgery and found a significant
decrease in delirium in the group receiving melatonin.
Al-Aama and colleagues [37] compared prophylactic
melatonin with placebo in a population of acutely ill eld-
erly patients and found that melatonin was associated with
a reduction in the incidence of delirium. De Jonghe and
colleagues [38, 39] evaluated the effect of prophylactic
melatonin versus placebo on the incidence of delirium in
patients requiring hip surgery and found no significant
difference. Hatta and colleagues [40] compared the mela-
tonin receptor agonist ramelteon prophylactically with
placebo in critically ill medical patients and found a
significant reduction in delirium in the ramelteon group.
Artemiou and colleagues [41] evaluated the use of prophy-
lactic melatonin in patients undergoing cardiac surgery.
They reported a delirium incidence of 8.4% versus 250
control patients in whom the incidence was 20.8%. How-
ever, there was no placebo in their trial, and the trial was
not blinded.
Rationale for proposed study
Delirium is common in ICU; it is associated with worse
outcomes when it occurs; and currently there are limited
therapies to prevent it. The studies evaluating melatonin as
a prophylactic agent suggest that melatonin could play an
important role in preventing delirium in the critically ill
[19]. However, these studies were small and conducted
with populations that do not include ICU patients. It is un-
clear whether these proposed benefits would be replicated
in an adequately powered, randomised controlled trial or if
they would translate to critical care. In the present study,
we will attempt to answer the question whether, in a popu-
lation of critically ill adults, prophylactic melatonin, com-
pared with placebo [42], decreases the prevalence, duration
and severity of delirium.
Martinez et al. Trials  (2017) 18:4 Page 2 of 10
Objectives
The primary objective of this trial will be to determine
whether melatonin given prophylactically decreases the
prevalence of delirium in critically ill patients. The
secondary objectives will be to determine whether
prophylactic melatonin decreases the severity and
duration of delirium, improves sleep quality, reduces
hospital and ICU LOS, improves morbidity and mortal-
ity, and reduces healthcare costs through reduced LOS
and intensity of medical therapy.
Trial design
This study will be a prospective, multi-centre, rando-
mised, placebo-controlled, double-blind, prophylactic
intervention trial of melatonin 4 mg versus placebo
given at 21:00 for 14 days or until ICU discharge to crit-
ically ill patients admitted to ICU with an expected ICU
LOS of at least 72 h (two arms, 1:1 allocation, parallel
design). A subgroup of 100 patients from the two main
research sites (Sir Charles Gairdner Hospital and John




This study will be conducted in closed ICUs of partici-
pating hospitals in Australia. ICUs currently involved are
all in university-affiliated teaching hospitals. We will re-
cruit 850 patients admitted to ICU with an expected
LOS of at least 72 h.
Eligibility criteria
Inclusion criteria
Patients admitted to a participating ICU identified by
the treating intensivist as having an expected total ICU
LOS of 72 h or more are eligible. Patients must be en-
rolled within 48 h of their ICU admission and receive
the first dose of the study drug on the day of enrolment.
Exclusion criteria
The exclusion criteria are patients younger than 18 years
of age; patients already receiving melatonin therapy be-
fore their admission to ICU; prior hypersensitivity reac-
tion to any of the components (sucralose and glycerol)
of the study drug; patients expected to be discharged
within 72 h of admission; expected/inevitable death
within 48 h of enrolment; pregnancy or breastfeeding;
patients who are non-English-speaking; patients whose
condition is not expected to improve adequately for
them to be able to be assessed with a Confusion Assess-
ment Method for the ICU (CAM-ICU) score during
their ICU stay; patients who are not able to be assessed
because of neurological problems that would affect their
ability to participate in CAM-ICU assessment (as judged
by the treating physician); no enteral route/nil by mouth
(melatonin is not available in intravenous formulation);
and hepatic impairment, defined as alanine aminotrans-
ferase greater than 500 IU/L, previous liver transplant or
liver cirrhosis of Child-Pugh classes B and C.
Interventions
Eligible participants will be randomised to receive mela-
tonin 4 mg or placebo at 21:00 for 14 consecutive nights
or until ICU discharge, whichever occurs first. This will
be given either orally or via nasogastric tube, depending
on the circumstances. All concomitant care and inter-
ventions that are normal practice for the ICU or based
on other trials are permitted.
A subset of 100 patients will also undergo two episodes
of polysomnographic testing overnight on days 2–3 and
days 5–7 of their ICU stay. This will occur only at the two
primary sites: Sir Charles Gairdner Hospital and John
Hunter Hospital.
Outcomes
All assessors using the CAM-ICU and the Confusion
Assessment Method for delirium severity (CAM-S) will
receive training in these assessment tools along with regu-
lar monitoring to ensure the tools are being applied
reliably. The primary outcome will be prevalence of delir-
ium. This will be measured and reported as delirium-free
assessments. The secondary outcomes will be (1) overall
prevalence of delirium, (2) duration of delirium, (3) sever-
ity of delirium, (4) sleep quality, (5) ICU and hospital
LOS, (6) morbidity and mortality and (7) healthcare costs.
Prevalence of delirium
The primary outcome will be the proportion of
delirium-free assessments as measured by the CAM-
ICU score. Prevalence rather than incidence has been
chosen because delirium on admission to ICU may not
be measureable, owing to many patients being intubated
and sedated and therefore unable to be assessed. Where
possible, we will measure baseline delirium and provide
an incidence in those patients. The CAM-ICU is widely
used and is the best-performing of the tools adapted for
use in ICU by non-psychiatrists, with a pooled sensitivity
of 80.5% and specificity of 95.9% [43, 44]. The CAM-
ICU will be used twice daily with all assessable patients
while they are receiving the study drug for 14 days or
until ICU discharge, whichever occurs sooner.
Secondary outcomes will include the following:
1. Overall prevalence of delirium: Patients will be diag-
nosed as delirious when they have at least one positive
CAM-ICU up to ICU discharge or day 14 after enrol-
ment if still in ICU.
2. Duration of delirium: Once the diagnosis of delirium is
made, duration will be recorded as how many subsequent
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days on which they have a positive CAM-ICU until ICU
discharge or day 14 after enrolment.
3. Severity of delirium: Severity will be assessed using
the CAM-S Short Form [45], which gives a score from 0
to 8. Considering that sleep is an important part of this
study, an additional question from the CAM-S Long
Form on the sleep-wake cycle has been included in the
assessment. Thus, a score from 0 to 10 will be recorded.
Indirect markers of delirium severity will also be re-
corded daily until ICU discharge or day 14 after enrol-
ment. These are (1) need for anti-psychotics or sedation
(total daily doses will be calculated); (2) need for physical
restraints; (3) patient participation in physiotherapy
sessions and mobilisation; and (4) patient removal of
intravenous lines, drains or catheters.
Sleep quality
Sleep quality will be measured by (1) daily patient/nurse-
rated sleep assessment (Richards-Campbell Sleep Ques-
tionnaire) while in ICU [46] and (2) patient-rated sleep
quality questionnaire after ICU discharge [47]. This will
be performed from 2 to 14 days after ICU discharge with
the timing dependent on the patient’s ability to participate.
Patients unable to participate will be omitted.
A subgroup of 100 patients will undergo sleep quality
assessments twice during their ICU stay using polysom-
nography. The hypothesis is that melatonin will increase
the quality and quantity of sleep compared with placebo.
These 100 patients will come only from either Sir
Charles Gairdner Hospital or John Hunter Hospital.
Patients included in the study at these sites will be se-
quentially allocated to the subgroup. Polysomnography
will be done between days 2 and 3 and between days 5
and 7 of the ICU stay. For logistical reasons, we will
have limited access to polysomnography. It will be avail-
able only from Monday through Thursday, and hence we
have not been able to randomise patients to this investi-
gation. It is expected that, by virtue of blinding and ran-
domisation, approximately 50% of patients will be from
the melatonin arm and 50% from the placebo arm. The
polysomnography protocol and reporting have been
standardised and agreed upon by senior sleep physicians
at the two main centres. Patients will not be in a single
room every time polysomnography is performed, be-
cause this is a pragmatic study and will reflect real-
world conditions as much as possible. Many participat-
ing units do not have single rooms for all of their
patients. The range of days is selected so that if patients
cannot undergo polysomnography because of proce-
dures, they could have it the following night. If polysom-
nography needs to be aborted, we will try to repeat it
within that range of days. This will aid in the under-
standing of sleep patterns in the critically ill and the bio-
logical mechanisms through which melatonin may work.
Several parameters will be generated by the sleep stud-
ies. Two sleep experts involved in the study design have
selected the following four variables as the most import-
ant (each will be a secondary outcome): (1) total sleep
time, (2) sleep efficiency, (3) percentage REM sleep and
(4) arousal index.
ICU and hospital length of stay
ICU and hospital length of stay will be recorded using
existing hospital patient data programmes linked to
medical records.
Morbidity and mortality
Standard ICU markers of morbidity and mortality will
be recorded on a daily basis until ICU discharge or day
14 after enrolment. These include (1) duration of mech-
anical ventilation measured as ventilator-free days; (2)
daily need for vasopressor use; (3) daily need for renal
replacement therapy; (4) re-intubation, delayed extuba-
tion or need for tracheostomy; (5) Sequential Organ Fail-
ure Assessment score for injury severity; (6) mortality at
28 and 90 days; and (7) destination after ICU discharge.
Healthcare costs
A medical economist will perform a cost-consequence
analysis based on LOS and intensity of medical therapy
while in ICU.
Participant timeline and recruitment
Patients will be screened on the morning handover for
eligibility. Baseline data will be recorded on day 0. Pa-
tients will be assessed each day and have the primary
and secondary outcomes recorded daily until ICU dis-
charge or day 14 after enrolment. Patients will be seen
on the ward between days 2 and 14 after ICU discharge
to complete the sleep questionnaire. Patients who have
been discharged home will be contacted by phone.
Patients will be followed through their hospital stay to
record ICU LOS, hospital LOS, and 28- and 90-day mor-
tality. The trial assessment schedule is displayed in
Table 1 and Fig. 1.
To allow for accurate recording of LOS, we will allow
for a 6-month period after the last patient is enrolled. If
there are patients still hospitalised at that point, the last
day of the 6-month period will be recorded to calculate
as their last day of hospital admission.
Sample size
On the basis of two sample size calculations, with an
alpha value of 0.05 and a power of 80%, a total of 850
patients will be recruited into the study, with 425
patients in each arm. Estimates of sample size were
made on the basis of percentage of delirium-free assess-
ments (the primary outcome). An audit of 100 patients
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at Sir Charles Gairdner Hospital and John Hunter Hospital
was used to obtain preliminary data to guide sample size
calculations where an average of 54% of assessments were
deemed delirium-free (SD 45%). The research group is aim-
ing to detect a 10% increase in the percentage of delirium-
free assessments. This would give us a sample size calcula-
tion of 319 per group. Adjustment for a non-parametric test
(15%) increases this to 367 per group. It is expected that up
to 10% of patients recruited into the study will not be assess-
able for delirium at any point during the study. To account
for this and for missing data/loss to follow-up, the sample
size was increased by 15% to 423 patients per group (total
rounded to 850). This sample size will also be sufficient to
analyse the secondary measures.
To prevent and treat the issue of likely missing data,
the follow-up period for the primary outcome is short
and data collection is electronic, with out-of-range and
missing alerts. There will be documentation of why data
are missing. This will help us to formulate reasonable
assumptions about observations that are missing [48].
To achieve adequate recruitment numbers, there will be
frequent reminders to the participating sites, and pro-
gress reports will be scheduled periodically.
Allocation, randomisation, compliance and blinding
Patients will be randomised to melatonin or placebo in a 1:1
ratio according to a computer-generated randomisation list,
stratified by site, with standard block sizes of six. An in-
dependent statistician other than the statistician analys-
ing the data will create the allocation sequence. This
randomisation list will be provided by the independent
statistician directly to the compounding pharmacy.
Each patient’s bottle will be labelled with a site-specific
randomisation number, which will become that patient’s
study number. Study sites will administer the content of
the study drug bottles sequentially to patients in the order
in which they are included in the study.
Each participating site’s principal investigator or research
coordinator will enrol patients. All patients will receive the
same interventions, except for the sleep studies, which will
be assigned by the principal investigators at the two sites
performing sleep studies. A flowchart of enrolment, alloca-
tion, follow-up and analysis is shown in Additional file 1.
When a patient is enrolled in the study, ‘Pro-MEDIC
study drug’ will be charted on the medication chart. The
ICU bedside nurse, using an oral/enteral syringe, will ad-
minister the study drug at 21:00 until discharge from
ICU or 14 days after enrolment, whichever occurs first.
The study drug will be prepared by a single private
compounding pharmacy that currently produces mela-
tonin suspension for the health department and has ex-
tensive experience in clinical trials. They will be given
the randomisation list and will prepare individual bottles
for each patient that will contain an amount of the study
Table 1 Time schedule of Pro-MEDIC enrolment, interventions and assessments










Liver function tests X X (days 0, 5 and 10)
CAM-ICU score X X X X X
CAM-S test (for patients found to be delirious) X X X X X
Record daily ICU interventions X X X X X
Record daily anti-psychotic and sedation use X X X X X
Record daily sleep aid measures X X X X X
RCSQ X X X X X
Use of physical restraints X X X X X
Physiotherapy participation X X X X X
Polysomnography X X
Assessment of sleep quality X
ICU and hospital LOS X
Hospital discharge destination X
Mortality at 28 and 90 days X
Abbreviations: CAM-ICU Confusion Assessment Method for the ICU, CAM-S Confusion Assessment Method for delirium severity, ICU Intensive care unit, LOS Length
of stay, Pro-MEDIC Prophylactic Melatonin for Delirium in Intensive Care, RCSQ Richards-Campbell Sleep Questionnaire
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drug to last for up to 14 days. Both melatonin and pla-
cebo will be made to look and taste the same. The mela-
tonin will be prepared as a 2 mg/ml solution. The drug
packs will be shipped from the compounding pharmacy
to each of the participating sites, and responsibility will
be assigned to the site’s principal investigator.
The shelf life of the melatonin suspension is
12 months. The project manager will co-ordinate with
the pharmacy to ensure sites have an adequate supply of
the study drug based on recruitment rates. Subjects may
withdraw their consent to participate in the study at any
time and for any reason.
Compliance will be indicated by the nurse’s signature
on the medication chart each day that the study drug is
administered to the patient. There will be no restriction
or change in the use of any sedative, analgesic or anti-
psychotic agents given, but the use of these medications
will be recorded.
The patients, the investigators, and the ICU doctors
and nurses looking after patients enrolled in the study
will be blinded to the treatment that patients are receiv-
ing. Only the independent statistician providing the allo-
cation list to the pharmacy, the compounding pharmacy,
and the independent data and safety monitoring com-
mittee (DSMC), should they need to investigate an ad-
verse event (AE), will know which is melatonin and
which is placebo.
A standardised process for unblinding will be in place
for all sites. Blinding will be broken only if the senior
treating ICU doctor feels that the drug is causing AEs to
the patient and it is necessary to know if the patient
received melatonin, such as in the case of anaphylaxis.
Other AEs may lead to cessation of the study drug but
would not be expected to require unblinding.
Data collection and management
Data will be collected and entered into a REDCap© [49]
electronic database behind a secure firewall. The RED-
Cap system will perform data entry validation. For the
non-primary sites, data can be entered into the REDCap
database, or the case report forms can be filled in manu-
ally and forwarded to the primary sites. Strict confidenti-
ality and privacy will be kept at all times. The data will
be stored in password-protected files and will be kept
for 15 years. The final database will be locked after all
information for the last patient has been entered and
provided to the statistician.
If a participant withdraws consent, the investigators
will ask permission to retain all data collected up to the
point of withdrawal and to collect survival status and
discharge destination data. If subjects cease the study
drug for any reason, data will still be collected and inter-
preted in an intention-to-treat analysis. The reason for
withdrawal will be recorded. No attempt will be made to
replace patients who withdraw from the study.
Statistical methods
Analyses will be conducted on both intention-to-treat
and per-protocol bases. All outcomes will be analysed
for superiority (two-sided) and considered statistically
significant at the 5% level. Baseline data will be recorded
and analysed for imbalances between the treatment
groups. The primary endpoint, percentage of delirium-
free assessments, will initially be analysed using a Mann-
Whitney U test to compare the two treatment arms.
Subsequent supporting analyses will be carried out using
Fig. 1 Time schedule of Prophylactic Melatonin for Delirium in Intensive
Care (Pro-MEDIC) enrolment, interventions and assessments. CAM-ICU
Confusion Assessment Method for the ICU, CAM-S Confusion Assessment
Method for delirium severity, ICU Intensive care unit, LOS Length of stay
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a negative binomial model with adjustments made for
number of assessments (accounting for withdrawals),
important covariates and baseline data where appropri-
ate. Secondary endpoints of any prevalence of delirium
during the 14 days and duration of delirium from first
onset will be analysed using a chi-square test with sup-
porting analyses of binary and ordinal logistic regression,
respectively, allowing adjustments for covariates. Sleep
quality analysis based on the Richards-Campbell Sleep
Questionnaire on each of days 2–14, the patient-rated
sleep questionnaire completed after day 14, and sleep
measurements derived from polysomnography done on
days 2–4 and 5–7 (total sleep time, sleep efficiency,
REM sleep percentage and arousal index) will all be ana-
lysed initially using a Mann-Whitney U test to compare
the two treatment arms and subsequently using linear
mixed models with fixed factors of treatment time and
their corresponding interaction, along with random pa-
tient effects. ICU LOS, total hospital LOS, mortality and
morbidity events will be analysed initially using Kaplan-
Meier curves and log-rank tests and subsequently using
Cox proportional hazards models. Individuals withdrawn
from the study early will be censored at the date of with-
drawal. Specific subgroup analysis of major outcomes
will be carried out, stratifying by age, sex, delirium med-
ical subgroup and delirium risk as per the prediction of
delirium in ICU patients (‘PRE-DELIRIC’) score. A fully
specified statistical analysis plan will be finalised and ap-
proved by statisticians at the two main hospitals before
the database is unlocked and opened. Data analysis is to
be carried out using the R software programme [50].
Data monitoring and safety
A DSMC will be made up of an independent intensivist,
an epidemiologist and a statistician. They will confer
after 100 patients have been enrolled and will review the
unblinded data to determine the need for early termin-
ation of the trial. Early termination will be decided on
the basis of either (1) safety concerns with the ongoing
review of all severe adverse events (SAEs) and suspected
unexpected severe adverse reactions (SUSAR) or (2) out-
standing benefits. The DSMC will report to the research
committee and make a recommendation after its review.
A similar interim analysis will be performed at the mid-
point of the study after enrolment of 400 patients.
The Haybittle-Peto stopping rule will be used in both ana-
lyses. Thus, if there is a probability of less than 0.001 in
either direction that the treatment and placebo are different,
the DSMC will recommend that the study be ceased.
Melatonin has no serious adverse reactions docu-
mented in the medical literature [51]. An AE caused by
either melatonin or its solution will be considered as any
untoward medical occurrence in a patient enrolled in
this study, regardless of its causal relationship to the
study treatment. AEs will be monitored with a checklist
of symptoms commonly associated with medications,
including headache, gastrointestinal symptoms, lethargy,
myalgias and skin symptoms.
Melatonin has a very safe therapeutic profile. Assess-
ment and documentation of AEs will be carried out by
the principal and associate investigators and will be in-
cluded in the data collection instrument. Once collected,
these will be reviewed and classified as AEs, SAEs or
SUSARs. The DSMC will have access to this information
as unblinded data.
The baseline mortality of ICU patients enrolled in trials
will be high because of the critical illness necessitating
admission. New organ failure in a high proportion of ICU
patients is not unexpected, regardless of optimal treat-
ment and study intervention. As such, and in keeping with
the advice of Cook and colleagues, events that are part of
the natural history of the primary disease process or ex-
pected complications of critical illness will not be reported
as SAEs in this trial unless they are thought to be causally
related to the study intervention [52].
Ethics and dissemination
Ethics approval has been sought and obtained from the
Sir Charles Gairdner Hospital Human Research Ethics
Committee in Western Australia and the Hunter New
England Human Research Ethics Committee in New
South Wales. The NSW Civil and Administrative Tribu-
nal (NCAT) has granted approval to conduct the clinical
trial in this state. Protocol amendments will be commu-
nicated to these ethics committees for approval.
Subject confidentiality is strictly held in trust by the
investigators and is extended to clinical data collected
and test results. No information will be released to any
third party without the prior written approval of the
participating institutions. Clinical data will not be
released without the written permission of the partici-
pating individuals, except for the DSMC where required.
Data will be identified only by the study’s subject identi-
fication number.
This study protocol has been written following the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist (Additional file 1). A
populated checklist (Table 1) and a figure (Additional
file 1) displaying the schedule of enrolment, interven-
tions and assessments have been provided. The results
of this trial will be written as an article that will be sub-
mitted to peer-reviewed medical journals for publication.
Consent
Informed consent will be obtained from the patients or,
when it is not possible for patients to consent for them-
selves, from their person responsible. The investigators
received approval from the NCAT to allow the inclusion
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of patients who are highly dependent on medical care.
In Western Australia, the study will be undertaken using
an emergency waiver of consent, as allowed for in the
National Health and Medical Research Council national
statement, in conjunction with acknowledgement from
the patient’s person responsible that he or she is not
aware of any reason why the patient would have chosen
not to participate. All patients will be followed and given
the opportunity to consent to continue in the study once
their capacity to consent is regained [53].
Discussion
Delirium is increasingly being recognised as a significant
issue in hospital and particularly in ICU. It is associated
with poorer outcomes for the patients, their families and
the wider community. Intensive care is an area where
the prevalence of delirium is higher than in the general
wards. There are multiple potentially modifiable risk fac-
tors but very limited effective pharmacological options
for either prevention or treatment.
To our knowledge, this trial will be the largest trial
evaluating melatonin as a prophylactic agent for delir-
ium in any setting, and certainly the largest in intensive
care. It will also be one of the larger trials evaluating any
prophylactic agent in intensive care. Currently, a trial by
van den Boogaard and colleagues is recruiting. They are
evaluating haloperidol as a preventative agent for ICU
delirium and plan to enrol 2145 patients into 3 arms.
However, haloperidol has potential side effects, whereas
melatonin is extremely safe, inexpensive and potentially
more acceptable to patients, with the rate of side effects
being less than placebo [51].
The polysomnography arm will be an insightful explana-
tory component of the study and, to our knowledge, will
be one of the largest series of polysomnography in the
ICU setting. It may open up further avenues for research
into sleep in critical care.
The choice of 4 mg of melatonin as a dose required
some consideration. The existing trials have used a var-
iety of doses ranging from 0.5 mg to 5 mg [37–39, 41].
Bourne and colleagues [54] used 10 mg to aid sleep and
found a carry-over effect to the following day. Therefore,
we feel that 4 mg is a practical dose within the range of
previous studies. Evidence exists confirming absorption
in critical care for similar doses, and this dose is unlikely
to have a significant carry-over effect the following day.
Melatonin (Circadin; Flynn Pharma, Dublin, Ireland),
the current Pharmaceutical Benefits Scheme listed agent,
also comes in 2-mg tablets.
Patients will be assessed for delirium on enrolment.
This will not be possible where patients arrive at the unit
ventilated and heavily sedated. Because of this, true inci-
dence will not be able to be established, and it is recog-
nised that some patients may already have delirium on
enrolment. The investigators feel it is important to keep
this a pragmatic trial. The decision to mandate that
patients be enrolled within 48 h of their ICU admission
was made to ensure that the study drug is given early in
patients’ stay.
The enrolment of patients who have an expected LOS
longer than 72 h is being done because patients with
increased LOS are more likely to develop delirium. Al-
though prediction tools for delirium do exist [55, 56],
they are complex, and we seek to maintain the generalis-
ability of our findings to a broad range of ICU patients.
Trial status
We are in the process of recruiting patients.
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